meldepliktige handler fra primærinnsidere

← Alle transaksjoner

Lytix Biopharma ASA (LYTIX)

Kjøp4
Salg0
Innsidere2
Netto siden 20211,5 mill. NOK
Kurs (ukentlig, 5 år) og innsidehandler kjøp salg— størrelse = beløp
58121520222023202420252026Kjøp 2025-12-11: Øystein Rekdal, 10 000 stk (99 984 NOK)

Vis kun reelle kjøp og salg

PublisertPersonRolleTypeVolumPrisVerdiHandelsdato
9. april 2026Darlene Deptula-Hicks Primary insider/Board memberAnnet Tildeling100 0000 NOK09. april 2026melding
9. januar 2026Saturn Invest AS nærstående–Tegning Emisjon/tegning2 222 2229 NOK19 999 9989. januar 2026melding
11. desember 2025Øystein Rekdal Chief Executive OfficerKjøp10 0009,9984 NOK99 98411. desember 2025melding
1. september 2025Mette Husbyn Chief Technology OfficerAnnet Tildeling341 3100 NOK01. september 2025melding
1. september 2025Gjest Breistein Chief Financial OfficerAnnet Tildeling615 6200 NOK01. september 2025melding
1. september 2025Baldur Sveinbjørnsson Chief Scientific OfficerAnnet Tildeling923 9300 NOK01. september 2025melding
1. september 2025Øystein Rekdal Chief Executive OfficerAnnet Tildeling1 627 8600 NOK01. september 2025melding
21. mai 2025Marie-Louise Fjällskog Member of the Board in Lytix Biopharma ASAnnet Tildeling40 0000 NOK021. mai 2025melding
21. mai 2025Kjetil Hestdal Member of the Board in Lytix Biopharma ASAnnet Tildeling40 0000 NOK021. mai 2025melding
21. mai 2025Julie Dehaene-Puype Member of the Board in Lytix Biopharma ASAnnet Tildeling100 0000 NOK021. mai 2025melding
21. mai 2025Eric Falcand Chair of the Board in Lytix Biopharma ASAnnet Tildeling100 0000 NOK021. mai 2025melding
21. mai 2025Claus Andersson Member of the Board in Lytix Biopharma ASAnnet Tildeling100 0000 NOK021. mai 2025melding
21. mai 2025Brynjar Forbergskog Member of the Board in Lytix Biopharma ASAnnet Tildeling40 0000 NOK021. mai 2025melding
27. desember 2024Saturn Invest AS nærstående–Annet Uklassifisert1 318 9130 NOK027. desember 2024melding
17. desember 2024Saturn Invest AS nærstående–Annet Uklassifisert1 318 9130 NOK017. desember 2024melding
17. desember 2024Øystein Rekdal Managing directorTegning Emisjon/tegning16 6666 NOK99 99616. desember 2024melding
17. desember 2024Saturn Invest AS nærstående–Tegning Emisjon/tegning3 166 6666 NOK18 999 99616. desember 2024melding
17. desember 2024Kjetil Hestdal Board memberTegning Emisjon/tegning13 5006 NOK81 00016. desember 2024melding
17. desember 2024Gjest Andreas Breistein Chief Financial OfficerTegning Emisjon/tegning16 6666 NOK99 99616. desember 2024melding
17. desember 2024Evelina Wanda Matilda Vägesjö Board memberTegning Emisjon/tegning4 2476 NOK25 48216. desember 2024melding
17. desember 2024Baldur Sveinbjørnsson Chief Scientific OfficerTegning Emisjon/tegning8 3336 NOK49 99816. desember 2024melding
26. april 2024Saturn Invest AS nærstående–Tegning Emisjon/tegning38 9100,1 NOK3 89126. april 2024melding
26. april 2024Hifo Invest AS nærstående–Tegning Emisjon/tegning38 9100,1 NOK3 89126. april 2024melding
25. april 2024Øystein Rekdal Managing directorTegning Emisjon/tegning9 5505,24 NOK50 04225. april 2024melding
25. april 2024Saturn Invest AS nærstående–Tegning Emisjon/tegning724 4485,24 NOK3 796 10825. april 2024melding
25. april 2024Hifo Invest AS nærstående–Tegning Emisjon/tegning724 4485,24 NOK3 796 10825. april 2024melding
25. april 2024Gjest Andreas Breistein Chief Financial OfficerTegning Emisjon/tegning10 0005,24 NOK52 40025. april 2024melding
25. april 2024Baldur Sveinbjørnsson Chief Scientific OfficerTegning Emisjon/tegning4 0005,24 NOK20 96025. april 2024melding
18. april 2023Marie Roskrow 2222 Reason for the notificationReason for the notificationReason for the notificationReason for the notification a) Position/status Chairperson of the Board in Lytix Biopharma AS Chairperson of the Board in Lytix Biopharma ASAnnet Tildeling60 0000 NOK018. april 2023melding
18. april 2023Marie-Louise Fjällskog 2222 Reason for the notificationReason for the notificationReason for the notificationReason for the notification a) Position/status Member of the Board in Lytix Biopharma AS Member of the Board in Lytix Biopharma ASAnnet Tildeling60 0000 NOK018. april 2023melding
18. april 2023Kjetil Hestdal 2222 Reason for the notificationReason for the notificationReason for the notificationReason for the notification a) Position/status Member of the Board in Lytix Biopharma AS Member of the Board in Lytix Biopharma ASAnnet Tildeling60 0000 NOK018. april 2023melding
18. april 2023Jayson Rieger 2222 Reason for the notificationReason for the notificationReason for the notificationReason for the notification a) Position/status Member of the Board in Lytix Biopharma AS Member of the Board in Lytix Biopharma ASAnnet Tildeling60 0000 NOK018. april 2023melding
18. april 2023Evelina Vågesjö 2222 Reason for the notificationReason for the notificationReason for the notificationReason for the notification a) Position/status Member of the Board in Lytix Biopharma AS Member of the Board in Lytix Biopharma ASAnnet Tildeling60 0000 NOK018. april 2023melding
18. april 2023Brynjar Forbergskog 2222 Reason for the notificationReason for the notificationReason for the notificationReason for the notification a) Position/status Member of the Board in Lytix Biopharma AS Member of the Board in Lytix Biopharma ASAnnet Tildeling60 0000 NOK018. april 2023melding
14. desember 2022Øystein Rekdal 2222 Reason for the notificationReason for the notificationReason for the notificationReason for the notification a) Position/status CEO in Lytix Biopharma AS CEO in Lytix Biopharma ASAnnet Tildeling420 0000 NOK014. desember 2022melding
14. desember 2022Gry Stensrud 2222 Reason for the notificationReason for the notificationReason for the notificationReason for the notification a) Position/status CTO in Lytix Biopharma AS CTO in Lytix Biopharma ASAnnet Tildeling67 0000 NOK014. desember 2022melding
14. desember 2022Gjest Breistein 2222 Reason for the notificationReason for the notificationReason for the notificationReason for the notification a) Position/status CFO in Lytix Biopharma AS CFO in Lytix Biopharma ASAnnet Tildeling67 0000 NOK014. desember 2022melding
14. desember 2022Baldur Sveinbjørnsson 2222 Reason for the notificationReason for the notificationReason for the notificationReason for the notification a) Position/status CSO in Lytix Biopharma AS CSO in Lytix Biopharma ASAnnet Tildeling100 0000 NOK014. desember 2022melding
1. september 2022North Murray AS nærstående–Kjøp33 5198,5656 NOK287 110–melding
27. august 2022North Murray AS nærstående–Kjøp125 0007,9714 NOK996 425–melding
26. august 2022Øystein Rekdal CEO in Lytix BiopharmaKjøp13 0007,7274 NOK100 456–melding

Atom-feed for denne utstederen